4.6 Article

Potential Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer

Journal

PLOS ONE
Volume 5, Issue 10, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0013073

Keywords

-

Funding

  1. National Cancer Institute (NCI) [P50-CA58223-09A1, RO1-CA138255]
  2. Breast Cancer Research Foundation
  3. V Foundation for Cancer Research

Ask authors/readers for more resources

Background: The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of breast cancer cases (60-80%). Methodology/Principal Findings: We find that c-Myb high expression in human breast tumors correlates with the luminal/ER+ phenotype and a good prognosis. Stable RNAi knock-down of endogenous c-Myb in the MCF7 luminal breast tumor cell line increased tumorigenesis both in vitro and in vivo, suggesting a possible tumor suppressor role in luminal breast cancer. We created a mammary-derived c-Myb expression signature, comprised of both direct and indirect c-Myb target genes, and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated with a mammary stem/progenitor lineage gene signature. Conclusions/Significance: These data describe, for the first time, a possible tumor suppressor role for the c-Myb protooncogene in breast cancer that has implications for the understanding of luminal tumorigenesis and for guiding treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available